JP2017506257A - 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法 - Google Patents

癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法 Download PDF

Info

Publication number
JP2017506257A
JP2017506257A JP2016558543A JP2016558543A JP2017506257A JP 2017506257 A JP2017506257 A JP 2017506257A JP 2016558543 A JP2016558543 A JP 2016558543A JP 2016558543 A JP2016558543 A JP 2016558543A JP 2017506257 A JP2017506257 A JP 2017506257A
Authority
JP
Japan
Prior art keywords
agx51
cancer
treatment
compound
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016558543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506257A5 (enExample
Inventor
ウィリアム， エー． ガーランド，
ウィリアム， エー． ガーランド，
ジャディブ チャウダリ，
ジャディブ チャウダリ，
グレン ストーラー，
グレン ストーラー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2017506257A publication Critical patent/JP2017506257A/ja
Publication of JP2017506257A5 publication Critical patent/JP2017506257A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016558543A 2013-12-13 2014-12-14 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法 Pending JP2017506257A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361916116P 2013-12-13 2013-12-13
US61/916,116 2013-12-13
US201461965776P 2014-02-06 2014-02-06
US61/965,776 2014-02-06
PCT/US2014/070221 WO2015089495A2 (en) 2013-12-13 2014-12-14 Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019162598A Division JP2019203028A (ja) 2013-12-13 2019-09-06 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法

Publications (2)

Publication Number Publication Date
JP2017506257A true JP2017506257A (ja) 2017-03-02
JP2017506257A5 JP2017506257A5 (enExample) 2018-02-01

Family

ID=53371974

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016558543A Pending JP2017506257A (ja) 2013-12-13 2014-12-14 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法
JP2019162598A Withdrawn JP2019203028A (ja) 2013-12-13 2019-09-06 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019162598A Withdrawn JP2019203028A (ja) 2013-12-13 2019-09-06 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法

Country Status (6)

Country Link
EP (1) EP3079680A4 (enExample)
JP (2) JP2017506257A (enExample)
CN (1) CN107847470A (enExample)
AU (1) AU2014361814A1 (enExample)
MX (1) MX2016007748A (enExample)
WO (1) WO2015089495A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550589A (ja) * 2019-10-01 2022-12-02 メモリアル スローン ケタリング キャンサー センター Ｉｄタンパク質の小分子阻害剤

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
CN113106053A (zh) 2015-04-21 2021-07-13 恩立夫克治疗有限责任公司 治疗性汇集的血液凋亡细胞制剂与其用途
EP3416661A4 (en) 2016-02-18 2020-03-04 Enlivex Therapeutics Ltd. COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER
LU100900B1 (de) * 2018-08-10 2020-02-17 Thomas Melchior Homann Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen
EP3760614B8 (en) * 2019-07-02 2022-04-27 Universität Heidelberg Chemical inhibitors of id proteins for the treatment of cancer and other diseases
CN113627763B (zh) * 2021-07-30 2023-12-01 厦门大学 一种风险量化评估模型建立方法
CN114480490A (zh) * 2021-12-31 2022-05-13 四川省医学科学院·四川省人民医院 一种构建视网膜新生血管性疾病动物模型的方法
CN115487358B (zh) * 2022-08-05 2023-05-30 核工业四一六医院 一种用于软骨组织修复的凝胶复合支架及制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226422A1 (en) * 2007-10-16 2009-09-10 Jaideep Chaudhary Chemical Inhibitors of Inhibitors of Differentiation
WO2012000036A1 (en) * 2010-06-30 2012-01-05 Garvan Institute Of Medical Research Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of differentiation 1
WO2013025939A2 (en) * 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226422A1 (en) * 2007-10-16 2009-09-10 Jaideep Chaudhary Chemical Inhibitors of Inhibitors of Differentiation
WO2012000036A1 (en) * 2010-06-30 2012-01-05 Garvan Institute Of Medical Research Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of differentiation 1
WO2013025939A2 (en) * 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMMEDCHEM (2013), 8(12), 1963-1977, JPN6018031672, 1 December 2013 (2013-12-01), ISSN: 0004025829 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550589A (ja) * 2019-10-01 2022-12-02 メモリアル スローン ケタリング キャンサー センター Ｉｄタンパク質の小分子阻害剤

Also Published As

Publication number Publication date
WO2015089495A2 (en) 2015-06-18
WO2015089495A3 (en) 2015-11-12
EP3079680A2 (en) 2016-10-19
JP2019203028A (ja) 2019-11-28
EP3079680A4 (en) 2017-11-22
AU2014361814A1 (en) 2016-07-28
MX2016007748A (es) 2017-07-28
CN107847470A (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
JP2019203028A (ja) 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法
KR101938431B1 (ko) 뇌 종양의 치료를 위한 csf-1r 억제제
US20140328940A1 (en) Modulation of axon degeneration
WO2009051801A2 (en) Chemical inhibitors of inhibitors of differentiation
CN107614062A (zh) 用RORγ抑制剂治疗癌症的方法
AU2013245630A1 (en) Treatment of ischemic retinopathies
US20140336129A1 (en) Targeting the EGFR-SGLT1 Interaction for Cancer Therapy
US10010581B2 (en) Syndecan peptides and polypeptides and uses thereof
US20200216906A1 (en) Methods and compositions relating to the diagnosis and treatment of cancer
Zhang et al. HHLA2 promotes tumor progression by long non‑coding RNA H19 in human gallbladder cancer
US20220280590A1 (en) Use of inhibitors of yap and sox2 for the treatment of cancer
JPWO2014007402A1 (ja) 眼細胞の分化マーカーおよび分化制御
EP1539247A2 (en) Alpha 5 beta 1 and its ability to regulate the cell survival pathway
US20240382476A1 (en) Androgen receptor biomarkers for cancer therapy
WO2023053142A1 (en) Novel combination of serotonin receptor (5-htr2b) antagonist and an immunomodulator and chemotherapeutic drugs for inhibition of cancer
US20200023038A1 (en) Method of treating neoplasias
CN120265328A (zh) 用于非小细胞肺癌的检测和治疗的方法
US11427543B2 (en) Compounds for targeting cancer stem cells
JP7684910B2 (ja) 小児対象において神経膠腫を治療するためのｔｇ０２の使用
US20150306216A1 (en) Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
US20160287575A1 (en) Compositions and methods for the treatment of diseases involving hippo pathway
WO2008046459A1 (en) Treatment of chemotherapy- or radiotherapy-resistant tumors using an l1 interfering molecule
US10213449B2 (en) Compositions and methods for treating medulloblastoma
JP2019535721A (ja) 抗癌剤としての選択的ｃ−ＦＬＩＰ阻害剤
Zhao et al. A review on molecular mechanisms underlying the contribution of Tspan8 and CD151 tumor and host exosomes to tumor progression, hematopoiesis and angiogenesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190507